Daily Endocrinology Research Analysis
Three high-impact endocrinology-related studies span pregnancy thyroid autoimmunity, metabolic liver disease progression, and early-life risk factors. An IPD meta-analysis shows dose-dependent associations between TPO antibodies and maternal thyroid function below standard positivity cut-offs, while two large cohorts link diabetes/long-term glycemia and childhood antibiotic exposure to MASLD trajectories and risk.
Summary
Three high-impact endocrinology-related studies span pregnancy thyroid autoimmunity, metabolic liver disease progression, and early-life risk factors. An IPD meta-analysis shows dose-dependent associations between TPO antibodies and maternal thyroid function below standard positivity cut-offs, while two large cohorts link diabetes/long-term glycemia and childhood antibiotic exposure to MASLD trajectories and risk.
Research Themes
- Pregnancy thyroid autoimmunity and functional thresholds
- Metabolic liver disease progression under diabetes and glycemic exposure
- Early-life exposures and long-term metabolic liver risk
Selected Articles
1. Interpretation of the association between thyroid peroxidase antibodies and thyroid function during pregnancy: An individual participant data meta-analysis.
Across 62,634 pregnancies from 24 cohorts, TPOAb percentiles showed dose-dependent associations with higher TSH, lower FT4, and increased risks of overt/subclinical hypothyroidism, most pronounced in early pregnancy. Notably, women with TPOAb levels below standard positivity cut-offs but above the 89th percentile still had substantially elevated risks, indicating clinically relevant thyroid autoimmunity.
Impact: This large IPD meta-analysis challenges reliance on manufacturer cut-offs and provides quantitative thresholds for risk stratification during pregnancy. It directly informs screening and follow-up of thyroid function in early gestation.
Clinical Implications: Consider closer monitoring when TPOAb concentrations are high-normal (≥~89th percentile) even if below assay positivity; prioritize early pregnancy testing to detect rising TSH and falling FT4; refine thresholds for initiating follow-up or treatment.
Key Findings
- Dose-dependent increase in TSH from the 89th to 100th TPOAb percentile (up to +1.04 SD at 100th percentile).
- Dose-dependent decrease in FT4 from the 91st to 100th TPOAb percentile (down to -0.48 SD at 100th percentile).
- Absolute risk of TSH >4.0 mU/L rose from 2.4% (≤80th percentile) to 4.0% (89th) and 28.1% (100th).
- Associations strongest in early pregnancy; some women below assay cut-offs still had elevated risk.
Methodological Strengths
- Individual participant data meta-analysis across 24 cohorts (n=62,634).
- Mixed-effects modeling with percentile-based exposure harmonization.
Limitations
- Observational cohorts may be subject to residual confounding.
- Heterogeneity in assays and cohort timing despite percentile harmonization.
Future Directions: Define pregnancy-specific TPOAb clinical thresholds prospectively and evaluate whether targeted monitoring/treatment based on high-normal TPOAb improves maternal-fetal outcomes.
BACKGROUND: Thyroid peroxidase antibody (TPOAb) positivity is the most important risk factor for hypothyroidism and determines thyroid function follow-up during pregnancy. TPOAb positivity is usually defined by manufacturer cut-offs which typically derived from non-pregnant populations. However, as a state of immune tolerance, pregnancy can affect TPOAb concentrations. To improve the understanding of clinical relevance of TPOAb concentrations during pregnancy, we investigated the associatio
2. Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD.
In 7,543 MASLD patients with serial VCTE and A1c, T2D independently increased risks of liver stiffness progression and liver-related events. Among T2D patients, poor long-term glycemic control (time-weighted average HbA1c ≥7%) was associated with faster stiffness progression, though not with regression or LREs.
Impact: This multi-center cohort uses time-weighted HbA1c and serial elastography to quantify how glycemic exposure drives fibrotic progression in MASLD, refining risk stratification beyond binary diabetes status.
Clinical Implications: Prioritize aggressive glycemic control (TWA HbA1c <7%) in MASLD with T2D to slow stiffness progression and intensify surveillance for those with T2D given higher LRE risk.
Key Findings
- T2D associated with higher risk of liver stiffness progression (HR 1.501; 95% CI 1.148-1.962; P=.003).
- T2D associated with higher risk of liver-related events (HR 2.030; 95% CI 1.241-3.320; P=.005).
- Among T2D, poor glycemic control (TWA HbA1c ≥7%) increased progression risk (HR 1.524; 95% CI 1.182-1.965; P=.001).
- No differences in stiffness regression or LREs by glycemic control level.
Methodological Strengths
- Large, multi-center cohort with 7,543 MASLD patients and serial VCTE measurements.
- Use of time-weighted average HbA1c capturing magnitude and duration of glycemic exposure; extensive sensitivity analyses.
Limitations
- Observational design limits causal inference.
- Potential misclassification of MASLD severity and unmeasured confounding.
Future Directions: Test whether intensifying glycemic targets slows histologic progression and reduces clinical events in MASLD through randomized trials; integrate glycemic exposure into prognostic models.
BACKGROUND & AIMS: The long-term impact of type 2 diabetes (T2D) status and long-term glycemic control on disease progression and clinical outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. The study sought to assess the association of diabetes status and long-term glycemic control with liver stiffness progression or regression, and liver-related events (LREs) in MASLD. METHODS: We analyzed patients with MASLD from the VCTE-Prognosis cohort who underw
3. Antibiotic consumption, genetic risk and incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
In 143,279 UK Biobank participants, early-life antibiotic exposure was associated with higher incident MASLD risk (HR 1.39), independent of genetic predisposition. Mediation analyses implicated metabolic syndrome (~22%) and central obesity (~14%), with a stronger effect in women.
Impact: Links a modifiable early-life exposure to MASLD risk at scale and quantifies metabolic mediators, informing prevention strategies beyond genetic risk.
Clinical Implications: Counseling to minimize unnecessary antibiotic exposure in childhood may reduce long-term MASLD risk; adults with such history may warrant targeted metabolic screening and lifestyle interventions.
Key Findings
- Early-life antibiotic exposure associated with higher incident MASLD (HR 1.39; 95% CI 1.21-1.59; P<0.001).
- No significant interaction between antibiotic exposure and MASLD genetic risk score.
- Mediation by metabolic syndrome (21.98%) and central obesity (13.55%); stronger association in women (P for interaction=0.031).
Methodological Strengths
- Very large prospective cohort with adjudicated incident MASLD and multivariable Cox models.
- Mediation analysis quantifying contributions of metabolic syndrome and central obesity; assessment of genetic risk interaction.
Limitations
- Antibiotic exposure likely based on recall/self-report for early life, introducing recall bias.
- Residual confounding and misclassification of MASLD cannot be excluded.
Future Directions: Validate findings with objective antibiotic exposure records and test whether microbiome-targeted or metabolic interventions mitigate MASLD risk in those with early-life exposure.
INTRODUCTION AND OBJECTIVES: The association between antibiotic consumption and the risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) remains ambiguous. This study aimed to investigate this relationship within a large prospective cohort from the UK Biobank. PATIENTS AND METHODS: We conducted a prospective cohort study of 143,279 adults aged 40 to 70 years, among whom 1477 were diagnosed with MASLD for the first time. Multivariate Cox proportional hazards regr